

Structure and Dynamics of Coxsackievirus B4 2A Proteinase, an Enzyme Involved in the Etiology of Heart Disease

Nicola J. Baxter,¹ Andreas Roetzer,³ Hans-Dieter Liebig,² Svetlana E. Sedelnikova,¹
Andrea M. Hounslow,¹ Tim Skern,^{3*} and Jonathan P. Waltho^{1*}

Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, United Kingdom¹; Axon Neuroscience GmbH, Rennweg 95b, 1030 Vienna, Austria²; and Max F. Perutz Laboratories, University Departments at the Vienna Biocenter, Institute of Medical Biochemistry, Medical University of Vienna, Dr. Bohr-Gasse 9/3, A-1030 Vienna, Austria³

Received 2 August 2005/Accepted 15 November 2005

The 2A proteinases (2A^{pro}) from the picornavirus family are multifunctional cysteine proteinases that perform essential roles during viral replication, involving viral polyprotein self-processing and shutting down host cell protein synthesis through cleavage of the eukaryotic initiation factor 4G (eIF4G) proteins. Coxsackievirus B4 (CVB4) 2A^{pro} also cleaves heart muscle dystrophin, leading to cytoskeletal dysfunction and the symptoms of human acquired dilated cardiomyopathy. We have determined the solution structure of CVB4 2A^{pro} (extending in an N-terminal direction to include the C-terminal eight residues of CVB4 VP1, which completes the VP1-2A^{pro} substrate region). In terms of overall fold, it is similar to the crystal structure of the mature human rhinovirus serotype 2 (HRV2) 2A^{pro}, but the relatively low level (40%) of sequence identity leads to a substantially different surface. We show that differences in the e1-to-e12 loop between HRV2 and CVB4 2A^{pro} translate to differences in the mechanism of eIF4GI recognition. Additionally, the nuclear magnetic resonance relaxation properties of CVB4 2A^{pro}, particularly of residues G1 to S7, F64 to S67, and P107 to G111, reveal that the substrate region is exchanging in and out of a conformation in which it occupies the active site with association and dissociation rates in the range of 100 to 1,000 s⁻¹. This exchange influences the conformation of the active site and points to a mechanism for how self-processing can occur efficiently while product inhibition is avoided.

Members of the picornavirus family include several common and important pathogens of humans, e.g., poliovirus, hepatitis A virus, rhinovirus (common cold), and coxsackievirus. Infection of heart muscle myocytes with coxsackie B viruses (members of the genus *Enterovirus*) is a significant etiological agent of human acquired dilated cardiomyopathy, being recognized in 30% of patients (1, 50). The disease is characterized by cardiac enlargement and congestive heart failure, and the pathological mechanism involves proteolytic cleavage by enteroviral 2A proteinases (2A^{pro}) of dystrophin (in the hinge-3 region) (2), leading to the disruption of the extrasarcomeric cytoskeleton and loss of transmission of mechanical force to the extracellular matrix (13, 54). The subsequent increased cell membrane permeability may facilitate effective release of new enterovirus particles from infected myocytes (61). The central role that dystrophin plays in the etiology of dilated cardiomyopathy (2, 3) is also substantiated in hereditary forms of the disease (Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy), which are characterized by mutations in the dystrophin gene (27, 33, 39, 55).

The genomes of the picornaviruses consist of single-stranded, messenger sense RNA molecules (7,500 nucleotides), which act as templates for both genomic replication and protein synthesis (see reference 32 and references therein). A polyprotein precursor is synthesized from the single open reading frame contained within the genome (Fig. 1), which is processed during translation by viral proteinases. The 2A^{pro} cleaves intramolecularly between the C terminus of VP1 and its own N terminus (56), termed the VP1-2A^{pro} substrate region, separating the capsid protein precursor from the non-structural protein precursor. All remaining cleavages are performed by the 3C proteinase or its precursor, 3CD proteinase (see reference 51 and references therein), yielding the mature viral proteins. The 2A^{pro} is a multifunctional enzyme which, in addition to viral polyprotein processing and dystrophin cleavage, plays an important role in shutting down the host's cellular metabolism in order to achieve optimum viral replication. The major cellular proteolysis targets of 2A^{pro} during the early stages of enteroviral and rhinoviral infection are eukaryotic initiation factors (eIFs) eIF4GI and eIF4GII. The eIF4G proteins, together with the cap-binding protein of cellular mRNAs (eIF4E) and the ATP-dependent RNA helicase (eIF4A), form the eIF4F complex responsible for the recruitment of capped mRNAs to the ribosome (for reviews, see references 25, 42, and 46). Cleavage of the eIF4G proteins by 2A^{pro} abolishes their scaffolding function within the eIF4F complex and between the eIF4F complex and part of the small ribosomal subunit (eIF3) (30), leading to the failure of translation initiation of cellular capped mRNAs (i.e., host cell shutoff) (17, 22). However, protein translation of picornaviral uncapped

* Corresponding author. Mailing address for Jonathan P. Waltho: Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, United Kingdom. Phone: 44 (0)114 222 2717. Fax: 44 (0)114 222 2800. E-mail: j.waltho@sheffield.ac.uk. Mailing address for Tim Skern: Max F. Perutz Laboratories, University Departments at the Vienna Biocenter, Institute of Medical Biochemistry, Medical University of Vienna, Dr. Bohr-Gasse 9/3, A-1030 Vienna, Austria. Phone: 43 1 4277 61620. Fax: 43 1 4277 9616. E-mail: timothy.skern@meduniwien.ac.at.




FIG. 1. Schematic representation of the picornaviral RNA genome. Genes for the following proteins are indicated. VP1 to VP4 are capsid proteins; 2A^{pro} and 3C^{pro} are proteinases responsible for proteolytic processing; 2B, 2C, and 3A are core proteins; VPg (genome-linked protein) is covalently attached to the 5' end of the RNA; and 3D^{pol} is the RNA-directed RNA polymerase. Prior to the completion of protein synthesis, the primary intramolecular proteolysis event is performed by 2A^{pro}, which cleaves between the C terminus of VP1 and its own N terminus, thereby separating the structural (capsid) protein precursor (P1) from the nonstructural protein precursor (P2 and P3). All subsequent proteolytic processing steps are performed by 3C^{pro} or its precursor, 3CD^{pro}. The internal ribosome entry sequence (IRES) contained within the 5'-nontranscribed region (NTR) is responsible for recruiting ribosomes to the viral RNA prior to protein synthesis via the cap-independent translation pathway.

RNA remains unaffected or even stimulated by cleavage of eIF4GI and eIF4GII, since initiation occurs directly at the internal ribosomal entry sequence contained in the 5'-nontranscribed region of the RNA genome (7). A second mechanism for the shutoff of host cell protein synthesis may also occur (26), involving the proteolytic cleavage by coxsackievirus 2A^{pro} of cytoplasmic poly(A)-binding protein, which mediates the translation initiation of eukaryotic mRNAs containing 3'-terminal poly(A) tracts.

A structural model of proteolytic cleavage by 2A proteinases was proposed based on a 1.95-Å-resolution crystal structure of 2A^{pro} from human rhinovirus serotype 2 (HRV2) (Protein Data Bank [PDB] accession no. 2HRV) (43). Intramolecular cleavage from VP1 had taken place prior to crystallization, and thus the structure represents the enzyme in the form that is active against the eIF4G proteins. This structure identifies 2A proteinases as members of the chymotrypsin-related protease family (the PA family of proteases) and comprises a four-stranded antiparallel β -sheet as the N-terminal domain and a larger C-terminal domain containing a six-stranded antiparallel β -barrel. The HRV2 2A^{pro} fold also contains a structural zinc ion coordinated tetrahedrally by three cysteine sulfur atoms and one histidine nitrogen atom. The zinc ion is tightly bound, and it can only be removed via chelation with EDTA upon denaturation of HRV2 2A^{pro} at low pH or at elevated temperature (53). The active site is located in the cleft between the two domains and consists of a catalytic triad involving His-18 (general base), Asp-35, and Cys-106 (nucleophile). The N terminus of HRV2 2A^{pro}, the P' product of the intramolecular cleavage reaction, is no longer within the active site but packs against the C-terminal domain distant from the active site cleft.

In the present study, we have determined the three-dimensional (3D) solution structure of the 19-kDa 2A^{pro} (EC 3.4.22.29) from coxsackievirus serotype B4 (CVB4) (strain JVB/Benschoten/New York/51). The protein employed comprises the last eight residues of CVB4 capsid protein VP1 (residues 274 to 281) positioned N terminally to the CVB4 2A^{pro} sequence (residues 1 to 150) (52) and thus represents

CVB4 2A^{pro} prior to intramolecular cleavage within the VP1-2A^{pro} substrate region. In addition, a single-amino-acid mutation at the catalytic cysteine nucleophile (C110A) was introduced to inactivate the 2A^{pro} as a proteinase in order to prevent self-cleavage. A BLAST alignment of 40 picornaviral 2A proteinase sequences indicates that CVB4 2A^{pro} and HRV2 2A^{pro} represent two extremes in the primary sequence diversity of the 2A^{pro} family. They share a relatively low (40%) level of amino acid sequence identity, leading to substantially different surface characteristics. In order to test our hypothesis that the mechanism of eIF4GI recognition by CVB4 2A^{pro} and HRV2 2A^{pro} is driven by different surface properties, we designed rationally a CVB4 2A^{pro} variant with improved eIF4GI cleavage efficacy.

MATERIALS AND METHODS

Plasmid preparation, protein expression, and purification. A DNA construct corresponding to an N-terminal polyhistidine sequence (His₆), the C-terminal eight amino acids of CVB4 VP1 (i.e., residues 274 to 281 [ERASLITT]), and CVB4 2A^{pro} containing a single-amino-acid mutation at the active site nucleophile (C110A) was cloned directionally between NcoI and BamHI restriction sites into a pET3d expression vector (Novagen). Following DNA sequence verification, *Escherichia coli* strain BL2(DE3) pLysE (Novagen) was transformed with the ligated vector pET3d/CVB4 2A^{pro}. Expression of CVB4 2A^{pro} was performed at 25°C in M9 minimal media containing 100 μ g/ml ampicillin and 32 μ g/ml chloramphenicol and was induced with 1 mM IPTG (isopropyl- β -D-thiogalactopyranoside). For ¹⁵N and ¹⁵N/¹³C uniformly labeled CVB4 2A^{pro} samples, 1 g (¹⁵NH₄)₂SO₄ per liter minimal medium and 1 g (¹⁵NH₄)₂SO₄ and 3 g [¹³C₆]glucose per liter minimal medium were used as the sole carbon and nitrogen sources, respectively. For the fractionally ¹³C-labeled sample, the carbon source in the minimal media contained both [¹³C₆]glucose and unlabeled glucose, mixed in a 1:9 ratio.

For protein purification, the cleared cell lysate in buffer A (50 mM NaCl, 50 mM Tris-HCl, pH 7.5) was applied to a DEAE-Sepharose fast-flow ion exchange column (Amersham Biociences) and CVB4 2A^{pro} was eluted from the column at 300 to 350 mM NaCl by use of a gradient (50 mM to 600 mM NaCl in buffer A). Fractions containing CVB4 2A^{pro} were pooled, an equal volume of 4 M ammonium sulfate was added to precipitate the proteinase, and the insoluble material was pelleted by centrifugation. The pellet was carefully suspended in 2 to 4 ml of buffer B (50 mM NaCl, 50 mM potassium phosphate, pH 8.1, 5 mM dithiothreitol [DTT]), in which the proteinase remained insoluble and was collected by centrifugation. Addition of a further 2 ml of buffer B to the pellet rendered the protein soluble (through further dilution of the remaining ammonium sulfate). Residual insoluble residue was removed by centrifugation, and the supernatant was applied to a Superdex-200 gel filtration column (Amersham Biociences). CVB4 2A^{pro} eluted as a sharp peak with a molecular mass of 19 kDa, corresponding to a monomer. The presence of the structural zinc ion following purification was determined using a Perkin Elmer Elan 6100 inductively coupled plasma (ICP) mass. Nuclear magnetic resonance (NMR) samples were prepared by combining fractions containing CVB4 2A^{pro} and were concentrated using a Vivaspin concentrator (Vivascience) up to 250 to 500 μ M (determined by the Bradford assay [7a]) in 50 mM potassium phosphate, 5 to 10 mM DTT, pH 7.6, 10% ²H₂O-90% H₂O (or 99.9% ²H₂O). The NMR samples were estimated to be greater than 95% pure based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). All protein purification steps and sample storage were performed at room temperature, as CVB4 2A^{pro} was found to be susceptible to cold denaturation.

NMR spectroscopy. NMR spectra of CVB4 2A^{pro} were acquired at a sample temperature of 303 K with a Bruker DRX series 500-MHz spectrometer equipped with a 5-mm triple-resonance cryoprobe and pulsed-field gradients, except where indicated otherwise. Proton chemical shifts were referenced to TSP [sodium 3-trimethylsilyl-2,2,3,3-(⁴H₄) propionate] at 0.0 ppm. ¹⁵N and ¹³C chemical shifts were calculated relative to TSP by use of the gyromagnetic ratios of ¹⁵N, ¹³C, and ¹H nuclei [$\gamma(^{15}\text{N})/\gamma(^1\text{H}) = 0.101329118$; $\gamma(^{13}\text{C})/\gamma(^1\text{H}) = 0.251449530$]. Resonance assignments for the HN, N, C α , C', C β , and H α nuclei were obtained from HNCA (23), HNCO (23), HN(CA)CO (14), CBCA(CO)HN (24), and HNCACB (Bruker DRX series 800-MHz spectrometer) (60) heteronuclear triple-resonance experiments and a 60-ms-mixing-time, ¹⁵N-edited, total correlated spectroscopy-heteronuclear single quantum correlation (TOCSY-

HSQC) (12) spectrum. Aliphatic side chain resonance assignment of ¹³C and ¹H nuclei beyond the C^β position was completed using HCCH- and CCH-TOCSY (6) and constant-time ¹³C-HSQC (58) spectra recorded for CVB4 2A^{PRO} in 99.9% ²H₂O. Aromatic side chain assignment was performed using constant-time ¹³C-HSQC optimized for aromatic couplings and ¹⁵N-filtered homonuclear TOCSY spectra (59), in conjunction with the simultaneously acquired ¹⁵N- and ¹³C-edited 3D nuclear Overhauser effect spectroscopy (NOESY) spectrum (100-ms mixing time) (41) used for obtaining nuclear Overhauser effects (NOEs) for the structure calculations. Stereospecific assignments of resolvable valine and leucine methyl groups were obtained using a 10% ¹³C-labeled CVB4 2A^{PRO} sample as described previously (37), with a Bruker DRX series 600-MHz spectrometer equipped with triple-axis gradients and a triple-resonance probe head. All spectra were processed and analyzed with Silicon Graphics workstations by use of FELIX 2000 software (Accelrys, Inc., San Diego, CA).

Structure determination. Sequence-specific assignments were obtained using the simulated annealing Monte Carlo algorithm Asstools (45). The assignment of ¹H, ¹⁵N, and ¹³C nuclei was nearly complete for CVB4 2A^{PRO} (residues 1 to 150); the levels of unambiguously assigned resonances were 78% of the total number of ¹H nuclei in the proteinase, 81% of the ¹⁵N nuclei in backbone amide groups, and 83% of the total number of ¹³C nuclei. ¹H-¹⁵N HSQC peaks corresponding to the remaining backbone amide groups were not observable. This is the result of exchange broadening and/or solvent exchange rather than a residual level of intramolecular proteolysis, since resonances from residues for which no ¹H-¹⁵N HSQC peaks were observable were present in ¹H-¹³C HSQC spectra, and the molecular weight was unaltered over the course of NMR data collection, as determined by SDS-PAGE. Resolvable stereospecific assignments were obtained for 20 out of 22 leucine methyl resonances and 28 out of 34 valine methyl resonances. ¹H and ¹⁵N resonance assignments for the labile side chain groups were not obtained, primarily due to solvent exchange at the relatively high pH of the system (pH 7.6). For residues P73, P79, and P91, the X-Pro peptide bond adopts a *trans*-conformation, as evidenced by the presence of strong H^α-H^β NOEs (no assignments were obtained for residues P2 or P107).

NOEs were assigned and distance restraints were derived from a simultaneously acquired ¹⁵N- and ¹³C-edited 3D NOESY spectrum (100-ms mixing time) by use of FELIX 2000, in-house macros, and UNIX scripts. Sequence-specific assignments were independently confirmed by sequential and medium-range NOE patterns. NOE cross-peak intensities were calibrated on the basis of a survey of covalently fixed distances and divided into two groups with upper bounds of 3.5 Å and 5.0 Å. Dihedral restraints were obtained from backbone and C^β chemical shifts by use of TALOS (15) and were implemented with a range of ±2 standard deviations from the predicted dihedral angle. Hydrogen bond restraints (d_{N-O} = 2.6 to 3.2 Å; d_{H-N-O} = 1.7 to 2.3 Å) were included for slowly exchanging backbone amides together with amide resonances within areas of regular secondary structure identified on the basis of backbone NOE patterns and by comparison with the HRV2 2A^{PRO} structure (43).

Initial structure calculations were performed without zinc ion restraints for residues 1 to 150 of CVB4 2A^{PRO}, using the dynamic annealing protocol provided with CNS version 1.1 (10). The expected zinc ion coordination site, comprising residues C56, C58, C116, and H118, adopted an approximate tetrahedral geometry in the absence of any explicit restraints to a zinc ion. In a subsequent refinement step, the zinc ion was incorporated into the structure calculations by employing appropriate covalent distance restraints [Cys(S^γ)-Zn ~ 2.3 Å; His(N^{δ1})-Zn ~ 2.1 Å] and angle restraints [Cys(S^γ)-Zn-Cys(S^γ) ~ 109°; His(N^{δ1})-Zn-Cys(S^γ) ~ 109°; Cys(C^β)-Cys(S^γ)-Zn ~ 109°; His(C^γ)-His(N^{δ1})-Zn ~ 120°] (40). One hundred structures were annealed from randomized starting coordinates, refined, and further refined incorporating the zinc ion into the structure. The 17 lowest energy structures were chosen to represent the structural ensemble.

Spin relaxation and amide exchange experiments. Longitudinal ¹⁵N relaxation times (T₁), transverse ¹⁵N relaxation times (T₂), and heteronuclear steady-state ¹⁵N-¹H NOE values were obtained using pulse sequences already described (28). Relaxation delays of 40, 80, 120, 180, 250, 500, 800, and 1,200 ms were used to calculate T₁, and delays of 20, 40, 60, 80, 100, 130, 160, and 180 ms were used to calculate T₂. For the ¹⁵N-¹H NOE measurement, two interleaved two-dimensional spectra were acquired, with a relaxation delay of 3.0 s between scans. Relaxation parameters were determined by fitting peak intensities measured using FELIX 2000 software. Hydrogen-deuterium amide exchange was initiated by diluting uniformly ¹⁵N-labeled CVB4 2A^{PRO} (ca. 600 μM in 50 mM potassium phosphate, 10 mM DTT, pH 7.6, in 10% ²H₂O-90% H₂O) with an equal volume of identical buffer prepared in 99.9% ²H₂O. The sample was equilibrated in the spectrometer at 303 K for 6 min prior to a series of 20 ¹H-¹⁵N HSQC spectra being recorded over a duration of 24 h. Slowly exchanging amide

groups were identified by fitting peak intensities, measured using FELIX 2000 software, to a single exponential function.

Molecular modeling. A model of CVB4 2A^{PRO} with the VP1-2A^{PRO} substrate region bound into the active site cleft was generated by first threading the wild-type CVB4 2A^{PRO} sequence (residues 1 to 150) onto the backbone coordinates of HRV2 2A^{PRO} (2HRV molecule A) (43) by using XPLOR version 3.1 (9). The model was then modified to include the C-terminal eight residues of CVB4 VP1 (ERASLITT), covalently attached at the proteinase N terminus by addition of residues with random coordinates. For the docking of the VP1-2A^{PRO} substrate region into the 2A^{PRO} active site, a list of close contacts between residues of the substrate and proteinase was derived based on both the crystal structure of the *Streptomyces griseus* protease B turkey ovomucoid (third domain) inhibitor complex (44) (PDB accession no. 3SGB) and the model of HRV2 2A^{PRO} binding an oligopeptide substrate (43). The identified close contacts between residue side chains were translated into ambiguous distance restraints (to include all side chain hydrogens) with upper bounds of 4.0 Å. Additionally, five similarly identified hydrogen bond restraints were included (d_{N-O} = 2.6 to 3.2 Å; d_{H-N-O} = 1.7 to 2.3 Å). The docking was carried out using the dynamic annealing protocol of CNS version 1.1 (10), in which the coordinates of ERASLITT and the first eight residues of the proteinase were allowed to move, while the coordinates of CVB4 2A^{PRO} (residues 9 to 150) remained fixed. Twenty structures were generated, and the structure closest to the average coordinates was selected as representative.

In vitro analysis of 2A^{PRO} self-processing and eIF4GI cleavage. In order to probe 2A^{PRO} self-processing and eIF4GI cleavage, two further plasmid constructs were prepared: (i) CVB4 VP1-2A^{PRO}, which contains the CVB4 nucleotides 2449 to 3741, encodes all of VP1 followed by all of 2A^{PRO}, terminating with two stop codons, and (ii) HRV2 VP1-2A^{PRO}, which contains the HRV2 nucleotides 2318 to 3586, encodes all but the first two amino acids of VP1 followed by all of 2A^{PRO}, terminating with two stop codons. In addition, CVB4 VP1-2A^{PRO} was mutated to carry a single-amino-acid mutation in 2A^{PRO} (R20L). The VP1-2A^{PRO} nucleotides were cloned downstream of the encephalomyocarditis virus internal ribosomal entry sequence in the plasmid pCITE (Novagen). Following linearization with BamHI, mRNA was transcribed in vitro from CVB4 VP1-2A^{PRO}, CVB4 VP1-2A^{PRO} R20L, and HRV2 VP1-2A^{PRO} and translated in vitro in rabbit reticulocyte lysates (RRLs) as described previously (20, 21). The in vitro translation reactions (typically 50 μl) contained 70% RRL (Promega), 20 μCi of [³⁵S]methionine label (1,000 Ci/mmol; Hartmann Analytic), 0.8 U of RNasin/μl, and unlabeled amino acids (except methionine) at 20 μM. After preincubation for 2 min at 30°C, translation was initiated by the addition of CVB4 VP1-2A^{PRO}, CVB4 VP1-2A^{PRO} R20L, or HRV2 VP1-2A^{PRO} mRNA to a final concentration of 10 ng/μl. Aliquots were taken at designated time points and placed on ice, and translation was terminated by the addition of unlabeled methionine and cysteine to a 2-mM concentration each, followed by Laemmli sample buffer. Proteins were separated by SDS-PAGE and examined either by fluorography (17.5% acrylamide) to detect the radiolabeled translation products or by immunoblotting (6% acrylamide) with an antibody against the N terminus of eIF4GI to monitor the status of endogenous eIF4GI in the RRL.

Protein structure accession number. The coordinates of the 17 lowest energy structures chosen to represent the structural ensemble have been deposited in the Protein Data Bank under accession no. 1Z8R.

RESULTS AND DISCUSSION

Solution structure of CVB4 2A^{PRO}. The three-dimensional solution structure of CVB4 2A^{PRO} (residues 1 to 150) was determined by multidimensional heteronuclear NMR methodology using a total of 1,857 experimentally determined restraints (Table 1), comprising 1,577 unambiguous NOE distance restraints, 168 dihedral angle restraints, and 56 × 2 hydrogen bond restraints. A high density of NOE restraints is present over a broad range of the primary sequence (Fig. 2), and in overall terms, the fold is well defined but with an unrestrained protein backbone for both termini and for two internal segments (Fig. 3). The per-residue root mean square (RMS) deviations from the average structure for the backbone atoms are included in Fig. 2. The regions that are less well defined correspond primarily to residues for which no sequence-specific resonance assignments could be identified, specifically for residues comprising the N-terminal polyhisti-

TABLE 1. CVB4 2A^{PRO} structural parameters^a

Parameter	Value
Experimentally determined restraints	
Unambiguous distance restraints	
Total	1,577
Intraresidue.....	678
Sequential	335
Medium range	95
Long range ($\Delta > 4$).....	469
Dihedral angle restraints	168
Hydrogen bond restraints	56 × 2
Stereospecific valine and leucine methyl groups	48/56
Nonexperimental restraints	
Zn ²⁺ protein bond restraints.....	4
Zn ²⁺ protein angle restraints.....	16
Deviations from the experimental restraints ^b	
NOE violations > 0.16 Å.....	2
Dihedral restraint violations > 2.5°	3
Mean RMS deviations from idealized geometry	
Bond lengths (Å)	0.00178 ± 0.00004
Angle geometry (°)	0.350 ± 0.007
Improper geometry (°)	0.213 ± 0.009
RMS deviations from the mean structure for well-defined regions ^c (Å)	
Backbone heavy atoms.....	0.47
All heavy atoms.....	1.03
Ramachandran analysis ^d	
Most favored regions (%).....	78
Additionally allowed regions (%).....	18
Generously allowed regions (%)	3
Disallowed regions (%).....	1

^a Ensemble of the 17 lowest energy structures out of a total of 100 calculated structures.

^b RMS NOE violation, 0.0119 ± 0.0004 Å; RMS dihedral violation, 0.45° ± 0.03°.

^c Residues 10 to 62, 70 to 102, and 112 to 147 (selected to exclude regions with low restraint densities [see Fig. 2]).

^d PROCHECK NMR (31) analysis of the structural ensemble. The percentages derived for the generously allowed and disallowed regions correspond to those residues that are ill defined or in loops in the structural ensemble (i.e., G1 to S7, F64 to S67, and P107 to G111).

dine sequence (His₆), the eight C-terminal residues of VP1, and the CVB4 2A^{PRO} segments G1 to S7, F64 to S67, and P107 to G111 (Fig. 4). For these residues, peaks in the ¹H-¹⁵N HSQC spectrum and the ¹⁵N-edited 3D spectra employed for backbone sequential assignment were reduced in intensity beyond detection.

The nomenclature used to label the β-strands in the structure of CVB4 2A^{PRO} (Fig. 3 and 4) follows that adopted for HRV2 2A^{PRO} (43), which is based on the topology of a member of the chymotrypsin family of serine proteases that shares a significant fold similarity with that of the picornaviral 2A^{PRO} family (*Streptomyces griseus* protease B [PDB accession no. 3SGB]) (44). The structure of CVB4 2A^{PRO} consists of an N domain containing a four-stranded antiparallel β-sheet (β-strands V10 to V12 [bI2], Y15 to N19 [cI], W33 to D35 [eI2], and L40 to T44 [fI]) and a C domain comprising a six-stranded antiparallel β-barrel (β-strands T60 to F64 [aII], H71 to E77 [bII1], V98 to T102 [cII2], I113 to R115 [dII], V120 to G127 [eII], and V131 to D136 [fII]) connected together by a long




FIG. 2. Structural parameters for CVB4 2A^{PRO}. (A) Distribution (number [No.]) of NOE restraints by residue. From bottom to top, intraresidue (white), sequential (light gray), medium-range (dark gray), and long-range (black) NOEs, respectively. (B) RMS deviations (RMSD) from the average structure for backbone atoms N, C^α, and C^β, plotted as separate data points for each residue. The arrows and bars along the top of the figure represent the regions of secondary structure. β-Strands of the N domain (I) are labeled b2, c, e2, and f, whereas those of the C domain (II) are labeled a, b1, b2, c1, c2, d, e, and f. Helical structures are labeled 1, 2, and 3.

interdomain loop (residues T46 to R55). Additionally, within the C domain, two β-strands (residues L81 to V84 [bII2] and R93 to S96 [cII1]) form an antiparallel β-hairpin (Fig. 3B, middle left), which makes close contact with residues from the N domain and was previously named the dityrosine flap (43). A β-bulge occurs at residues T125 and M126 on strand eII, which form hydrogen bonds with the carbonyl oxygen atom of G133. Three helical regions have been identified in the structure. A helical turn (α1; residues R20 to L22) follows β-strand cI, and a short α-helix (α2; residues H25 to Q29) lies between β-strands cI and eI2. Finally, close to the C terminus, a one-turn helix (α3; residues V137 to D139) is present. The hydrophobic core of CVB4 2A^{PRO} is composed almost exclusively of aliphatic hydrophobic residues (valine, leucine, and isoleucine). Unusually, the majority of aromatic residues are exposed on the surface: 8 of 9 Tyr residues, 2 of 4 Phe residues, 2 of 3 Trp residues, and 7 of 7 His residues.

Four highly conserved residues present in all members of the picornaviral 2A^{PRO} family serve to coordinate a very tightly bound zinc ion, which is required for the formation of enzymatically active proteinases (53, 57). The presence of zinc in CVB4 2A^{PRO} following purification was confirmed using ICP mass spectrometry. The tetrahedral coordination site for the




FIG. 3. 3D backbone structure and topology of CVB4 2A^{PRO}. (A) Stereoview overlay of the 17 lowest energy structures comprising the structural ensemble. The overlay was performed using the backbone atoms (N, C^α, and C') of residues 10 to 62, 70 to 102, and 112 to 147. (B) MOLSCRIPT (29) diagram of the representative structure of CVB4 2A^{PRO}, shown in the same orientation as for panel A. β-Strands in the N domain (bI2, cI, eI2, and fI) and in the C-terminal domain (aII, bII1, bII2, cII1, cII2, dII, eII, and fII) are labeled following the nomenclature adopted by Petersen et al. (43). The regions exhibiting a helical structure are labeled 1, 2 (α-helix between strands cI and eI2), and 3. The residues comprising the catalytic triad (H21, D38, and C110A) and those involved in zinc ion coordination (C56, C58, C116, and H118) are depicted as wire frames, and the zinc ion is shown as a gray sphere.

zinc ion within CVB4 2A^{PRO} was apparent without the explicit inclusion of the metal ion in the structure calculation and comprises three cysteine sulfur atoms and one histidine nitrogen atom. Two of the ligands [C56(S^γ) and C58(S^γ)] are donated from the end of the interdomain loop (Fig. 3B), whereas the other two ligands [C116(S^γ) and H118(N^{δ1})] are provided by a tight hairpin loop between β-strands dII and eII in the C domain. The subsequent incorporation of the tetrahedrally coordinated zinc ion into the CVB4 2A^{PRO} structure by use of

covalent distance and angle restraints was readily accommodated without major perturbations of the protein backbone.

The residues of the catalytic triad are found in the cleft formed between the N domain and the C domain (Fig. 3). The general base (H21) lies in a helical turn (α1) following β-strand cI, and D39 projects from a loop formed between β-strands eI2 and fI. The nucleophile (replaced by A110 in this CVB4 2A^{PRO} construct) is contained in a highly conserved amino acid sequence (PGDCGG) that forms a loop (termed the “active site loop”) between β-strands cII2 and dII in the C domain. However, this sequence is one of the unrestrained segments (P107 to G111) and therefore the precise geometrical relationship that this loop makes with the other structurally well-defined members of the catalytic triad cannot be determined.

Comparison with the HRV2 2A^{PRO} structure. CVB4 2A^{PRO} and HRV2 2A^{PRO} share approximately 40% sequence identity (Fig. 4). A pairwise backbone atom overlay (N, C^α, C', and O) of residues located in well-characterized structural segments of HRV2 2A^{PRO} with members of the CVB4 2A^{PRO} structural ensemble shows that the structures align closely (Fig. 5). The average pairwise RMS deviation for well-defined regions (Fig. 5) is 2.14 ± 0.06 Å, which is in the range typically found for the comparison of solution and crystal structures. The position and coordination of the zinc ion within the CVB4 2A^{PRO} structure also match the equivalent situation in HRV2 2A^{PRO}. Apart from the termini and the two unrestrained loops, the major differences between the two 2A^{PRO} structures occur within residues L22 to V32 of the N domain (L19 to I28 in HRV2 2A^{PRO}) (region I) and residues Q85 to P91 of the C domain (Q81 to P87 in HRV2 2A^{PRO}) (region II). For CVB4 2A^{PRO}, region I adopts a well-characterized α-helix (α2) and contains an additional amino acid (H25) compared to the HRV2 2A^{PRO} sequence (Fig. 4). In HRV2 2A^{PRO}, the equivalent region I displays high-temperature factors for both molecules A and B in the asymmetric unit (PDB accession no. 2HRV) (43). Upon superimposing molecules A and B of HRV2 2A^{PRO}, for residues




FIG. 4. Sequence alignment of CVB4 and HRV2 2A proteinases, including their respective C-terminal VP1 sequences. The position of the scissile bond between the C terminus of VP1 and the N terminus of 2A^{PRO}, present in the wild-type system, is indicated by an asterisk. Residues of the catalytic triad are boxed by solid lines (in this study, CVB4 2A^{PRO} carries a single-amino-acid mutation, C110A, which inactivates the enzyme), and residues that coordinate the zinc ion are boxed by dotted lines. Secondary-structure elements are indicated by arrows (β-strands) and bars (helical regions) and are labeled according to the scheme adopted by Petersen et al. (43). Horizontal dotted lines indicate contiguous residues of CVB4 2A^{PRO} for which peaks were reduced in intensity beyond detection in the ¹H-¹⁵N HSQC spectrum.




FIG. 5. Comparison of CVB4 2A^{pr} and HRV2 2A^{pr} structures. Stereo backbone traces (A and B) showing the overlay of two representative members of the CVB4 2A^{pr} NMR structural ensemble (red and magenta) together with molecule A of the HRV2 2A^{pr} crystal structure (black). The representative structures of CVB4 2A^{pr} were chosen to illustrate the extremes of backbone positioning for the region P107 to G111. The overlay was performed with MIDAS (18) by using the backbone atoms (N, C^α, C', and O) for residues in well-characterized structural segments (for CVB4 2A^{pr}, residues 10 to 21, 33 to 62, 70 to 84, 92 to 101, and 113 to 141, and for HRV2 2A^{pr}, residues 7 to 18, 29 to 58, 66 to 80, 88 to 97, and 109 to 137). The pairwise RMS deviations between the CVB4 2A^{pr} and HRV2 2A^{pr} structures are 2.13 Å (red-black) and 2.19 Å (magenta-black). In panel A, the orientation of the figure is identical to that presented in Fig. 3, whereas in panel B the molecule has undergone a rotation of 90 degrees about the vertical axis. Electrostatic potential surface representations of (C) CVB4 2A^{pr} and (D) HRV2 2A^{pr} are shown, oriented as in panel B. The surface was generated using GRASP (38), with limiting values of ±10.

1 to 139 the RMS deviation is 1.2 Å and the largest conformational difference between the two forms locates to region I. In molecule A this region adopts a short 3_{10} -helix, and in molecule B it is an unstructured loop translated by up to 6 Å from the atom positions defined for molecule A. Region II includes the β -hairpin loop between strands bII2 and cII1 (the dityrosine flap), which for HRV2 2A^{pr} in the crystal has the least well defined electron density and exhibits the highest temperature factors.

Mobility within the CVB4 2A^{pr} structure. In order to determine whether the differences between the structures of HRV2 2A^{pr} and CVB4 2A^{pr} are the result of motion within these regions, the mobility of the backbone of CVB4 2A^{pr} was characterized by measuring ^{15}N T_1 and T_2 relaxation times and heteronuclear steady-state ^{15}N - $\{^1\text{H}\}$ NOE values for backbone nitrogen atoms (Fig. 6). The correlation time for CVB4 2A^{pr} was calculated to be approximately 11 ns. The ^{15}N relaxation data demonstrate that CVB4 2A^{pr} has unusually little internal motion on a subnanosecond timescale over essentially the whole length of the protein, except for the C-terminal five residues, indicating that the structure is very tightly packed, even in the loops between secondary-structure elements. This lack of mobility is in part conferred by the shortness of loops,

which is a common feature of picornaviral proteinases (49). The tight packing includes both regions I and II with high-temperature factors in HRV2 2A^{pr} (43). Hence, the variation in conformation of HRV2 2A^{pr} in these regions is not reflected in high frequency flexibility within CVB4 2A^{pr}.

More apparent within the NMR relaxation behavior is the presence of conformational dynamics on a longer timescale, in the millisecond range, which results in the reduction of NMR signal intensity in the ^1H - ^{15}N HSQC spectrum beyond the limits of detection for residues within the VP1-2A^{pr} substrate region, the active site loop (P107 to G111) and its neighboring hairpin loop (F64 to S67) (Fig. 4), and residues N19, Q85, and L114. Additionally, ca. 30 residues, present mainly in the C domain, display significant reductions in ^1H - ^{15}N HSQC peak intensity. These intensity reductions are not the result of rapid exchange between amide hydrogens and the solvent. Although solvent exchange is observed for a few residues with high surface exposure, it is restricted only to those that have very high intrinsic exchange rates. Confirmation that low-frequency dynamics rather than amide solvent exchange is the primary cause of intensity reduction is provided by equivalent line-broadening effects being observable for some carbon-bound




FIG. 6. ^{15}N T_1 and T_2 relaxation times and heteronuclear steady-state ^{15}N - $\{^1\text{H}\}$ NOE values by residue for backbone nitrogen atoms in CVB4 2A^{PRO}.

hydrogen resonances within the VP1-2A^{PRO} substrate region and segments P107 to G111 and F64 to S67.

The line-broadening behavior is indicative of a conformational dynamics process occurring between two (or more) sim-

ilarly populated forms. The effects on the NMR signals of residues immediately flanking the regions where no signal intensity can be observed provide indications of the timescale of the conformational dynamics. The lack of a significant effect on ^{15}N T_2 rates in the flanking regions (Fig. 6) indicates that the dynamics are faster than the chemical shift differences of ^{15}N resonances in the relevant conformations. In contrast, there is widespread perturbation of ^1H resonances in flanking regions, indicating that the difference in ^1H chemical shift between conformations is similar to the frequency of the conformational dynamics (i.e., the intermediate exchange regime for ^1H). Most of the differences in ^1H chemical shifts between the interconverting conformations would fall in the range of 0.2 to 2.0 ppm, which equates to the conformational dynamics occurring in a frequency range of 100 to 1,000 s^{-1} .

Sources of conformational exchange dynamics. The most likely source of the low-frequency dynamics is the exchange of the VP1-2A^{PRO} substrate region in and out of the active site cleft. However, the widespread distribution of the resonance intensity reductions (Fig. 7A) indicates that the perturbations are not limited to the immediate site of contact between the substrate and the cleft. Additionally, the regions showing resonance intensity reductions are not uniformly distributed around the active site cleft. The dityrosine flap region (residues Q85 to K92) on one side of the substrate-binding cleft (Fig. 7A, middle left) is affected only to a moderate extent by the conformational exchange process, whereas a far larger perturbation is observed to occur in the active site loop (P107 to G111), which contains the active site nucleophile (alanine substituted in the present case, i.e., A110), and its adjacent hairpin loop (residues F64 to S67).

The substantial involvement of the F64 to S67 hairpin loop (located between β -strands aII and bII1 [Fig. 3B]) in the con-




FIG. 7. Model of the VP1-2A^{PRO} substrate region bound in the active site of wild-type CVB4 2A^{PRO}. (A) The VP1 C-terminal sequence ERASLITT, which is covalently attached at the N terminus of CVB4 2A^{PRO}, together with the first eight residues of the proteinase (GPYGHQSG), is shown as a green wireframe. The scissile bond is shown in purple. The CVB4 2A^{PRO} structure (residues 9 to 150) is depicted as a solvent accessible surface. The residues that are colored white (19, 64 to 67, 85, 107 to 111, and 114) have no discernible peaks in the ^1H - ^{15}N HSQC spectrum, and residues colored yellow display significantly reduced signal intensity. Residues of the catalytic triad (H21, D39, and C110) are colored red. The protein surface colored green (residue A9) represents the position where the wireframe is attached. Note that the protein surface occluding the substrate is formed by the close proximity of two distal regions of the protein (the dityrosine flap and P107 to G111). (B) Stereo wireframe representation of the active site, in which the VP1-2A^{PRO} substrate sequence (residues LITTG, corresponding to P4 to P1') is colored green and the residues of the catalytic triad are labeled (H21, D39, and C110). Residues S87 to Y89 are part of the dityrosine flap, residues E106 to G111 are part of the active site loop, and residues C65 to S67 are part of the adjacent hairpin loop. Panels A and B are oriented as in Fig. 3 and were prepared using PYMOL (16) and MOLSCRIPT (29)/Raster3D (36), respectively.

formational exchange process points to the role that this loop plays in defining the geometry of the oxyanion hole within proteinases. The oxyanion hole is a conserved motif in all chymotrypsin-like proteinases, which serves to stabilize the negative charge present on the P1 carbonyl oxygen atom of the tetrahedral intermediate via two precisely orientated backbone amide groups situated on the active site loop. By comparison with the HRV2 2A^{Pro} structure (43), the analogous hydrogen bond network in wild-type CVB4 2A^{Pro} (modeled in Fig. 7B) involves hydrogen bonds between the amide hydrogens of C110 and G108 and the carbonyl group of P1-T, the threonine residue involved in the scissile bond. The network also involves hydrogen bonds between the side chain of D109 and the backbone amide hydrogens of residues A66 and S67, which serves to stabilize the oxyanion hole by anchoring the active site loop to the adjacent hairpin loop (Fig. 7B). Additional backbone conformational restriction of the active site loop is provided by two hydrogen bonds between residues D109 and E106 and by an imidazolium-thiolate ion pair involving the general base (H21) in the N domain and the catalytic nucleophile in the C domain (47). As CVB4 2A^{Pro} carries a mutation of the catalytic nucleophile (C110A), part of the stabilization of the oxyanion hole is missing for this protein.

The distribution of the ca. 30 amide groups that display a significant reduction in peak intensity in the ¹H-¹⁵N HSQC spectrum (Fig. 7A) resulting from the conformational exchange process spreads well beyond the oxyanion hole. The overwhelming majority participate in intramolecular hydrogen bonds in the C domain β-barrel (17 amide groups), segments of the proteinase involved with binding substrate (9 amide groups), interdomain hydrogen bonds (3 amide groups), and cross-strand hydrogen bonds of the N domain (2 amide groups). A minimum model consistent with the data is one where the occupancy of the active site cleft by the VP1-2A^{Pro} substrate region (Fig. 7A) leads to the predominant population of the active conformation (similar to that observed for HRV2 2A^{Pro}), while nonoccupancy leads to a breakdown of the oxyanion hole conformation and a more widespread destabilization of the C-terminal β-barrel and its relationship to the N domain.

A related scenario has been observed for another viral chymotrypsin-like proteinase. The N-terminal proteinase from the hepatitis C virus NS3 protein (NS3 proteinase) requires the NS4A cofactor for efficient proteolytic processing of the viral polyprotein. In the absence of NS4A, the N-terminal β-barrel displays both substantial millisecond and subnanosecond time-scale mobility and is generally less well defined than the C-terminal β-barrel (4). The binding of an inhibitor (and by implication the substrate) is required for the stabilization and full positioning of its catalytic machinery (5). Upon the formation of a complex between NS3 proteinase and the proteinase-binding segment of its cofactor NS4A (in a single-chain construct in the absence of substrate), stabilization of the architecture of the catalytic triad is observed. However, conformational changes throughout large regions of the N domain are also apparent, resulting from positional exchange of the NS4A region between being bound to the NS3 proteinase and being released into solution (35). These dynamics are a consequence of substantial conformational plasticity within the N-terminal domain of NS3 proteinase. However, while the

NS3/NS4A system and CVB4 2A^{Pro} display substantial dynamic behavior (albeit in different domains), this is not a feature of chymotrypsin-like proteinases in general; for example, the subtilase family member PB92 has a predominantly rigid structure, with the exception of high-frequency dynamics within some surface loops and within a small number of residues closely involved in substrate binding in the active site cleft (34).

An alternative (or supplementary) explanation of the widespread distribution of the intensity reductions in CVB4 2A^{Pro} (Fig. 7A) is that the VP1-2A^{Pro} substrate region exchanges between two sites, in both of which it is bound to the proteinase. One conformer would involve the VP1-2A^{Pro} substrate region being bound in the active site cleft, while the second conformer would have the VP1-2A^{Pro} substrate region bound to the surface of 2A^{Pro} away from the active site. Binding at the second site would thus make a substantial contribution to the distribution of resonance intensity reduction. This behavior would mirror the repositioning of the N terminus of HRV2 2A^{Pro} following cleavage from its VP1 protein (43). In this scenario, the CVB4 VP1-2A^{Pro} substrate region would not be positioned exactly as that of the N terminus of HRV2 2A^{Pro} in the crystal, since the NMR signals in the corresponding region of the CVB4 2A^{Pro} are relatively unaffected by the exchange process. However, such a variation between the two proteins in the interaction surface is likely, given the sequence diversity between HRV2 2A^{Pro} and CVB4 2A^{Pro} (Fig. 4).

Functional significance of conformational exchange dynamics. Generally, 2A^{Pro} family members are relatively inefficient enzymes; the K_m values are approximately 10^{-4} M, while k_{cat} rate constants are approximately 1 s^{-1} (32, 51). Hence, whether the low K_m values are associated solely with weak binding or are affected by competing proteinase surface binding sites for the substrate, a conformational exchange rate in the range of 100 s^{-1} to $1,000\text{ s}^{-1}$ translates to the VP1-2A^{Pro} substrate region making hundreds or thousands of visits to the active site prior to cleavage. This means that the equilibrium constant between the two conformers, rather than the rate constant of conformational exchange, is important for the turnover of VP1-2A^{Pro} substrate cleavage. Maintaining this equilibrium in favor of the occupation of the active site cleft therefore assists proteolysis, while maintaining this equilibrium against the occupation of the active site minimizes product inhibition following cleavage of the VP1-2A^{Pro} substrate region. Product inhibition is a feature of other chymotrypsin-like proteinases; for example, in the maturation of α-lytic proteinase, the C terminus of the cleaved Pro region remains in the active site and inactivates the enzyme (48). Hence, an equilibrium constant in the region of unity for the exchange of the VP1-2A^{Pro} substrate region in and out of the active site (whether to solution or to an alternative surface binding site) represents a good compromise between the demands of VP1-2A^{Pro} substrate cleavage and the avoidance of product inhibition.

The surface properties of CVB4 and HRV2 2A^{Pro} have mechanistic implications. We have shown recently (19) that the efficient cleavage of eIF4GI by HRV2 2A^{Pro} is mediated by an interaction with eIF4GI via an exosite on the proteinase surface, which lies between residues L17 and D35 of the N domain (Fig. 5). The interruption of this interaction by the introduc-




FIG. 8. Kinetics of self-processing and eIF4GI cleavage by HRV2 2A^{PRO} and CVB4 2A^{PRO}. RRLs were incubated with the indicated mRNAs (~10 ng/μl). Samples were taken at the designated time points after mRNA addition, and protein synthesis was terminated by addition of unlabeled methionine and cysteine to 2 mM each and Laemmli sample buffer. Aliquots were then analyzed by PAGE; protein standards in kDa are indicated at left of blots. (A) Fluorogram of PAGE (17.5% acrylamide) showing protein synthesis. The positions of the uncleaved precursor VP1-2A^{PRO} and the cleavage products VP1 and 2A^{PRO} are marked. The fluorogram was exposed for 15 h at -80°C. (B) Immunoblot of PAGE (6% acrylamide), showing the status of eIF4GI. The positions of the uncleaved eIF4GI and the N-terminal cleavage product (cp_N) detected by the anti-eIF4GI antiserum are marked. (C) Fluorogram and immunoblot of CVB4 2A^{PRO} activity at longer time points. -RNA, without addition of mRNA.

tion of specific mutations was detrimental to the rate of eIF4GI cleavage, and indeed in certain cases eIF4GI cleavage was completely inhibited. The structure of CVB4 2A^{PRO} is well defined in this region (between R20 and D39), and comparison of the surface properties (Fig. 5C) with those of the parallel region in HRV2 2A^{PRO} (Fig. 5D) shows that this region in CVB4 2A^{PRO} is significantly more polar than that in HRV2 2A^{PRO}. Specifically, the two residues R20 and E34 in CVB4 2A^{PRO}, which are predicted to form a salt bridge, are largely responsible for the polar nature of this region. In contrast, the equivalent interaction in HRV2 2A^{PRO} connects residues L17 and V30 and is thus considerably more hydrophobic. The nature of this interaction in turn influences the position of the side chain of Y32 (Y36 in CVB4 2A^{PRO}). In HRV2 2A^{PRO}, the

combined result is an extensive hydrophobic surface, whereas the surface of CVB4 2A^{PRO} in this region is much more polar.

To investigate whether these differences in surface character affect the rates of self-processing or of eIF4GI cleavage, in vitro mRNAs corresponding to the VP1-2A^{PRO} proteins of HRV2 and CVB4 were synthesized and translated in RRLs in the presence of [³⁵S]methionine. As previously noted with HRV2 2A^{PRO} (21), the initial product of protein synthesis in this system is the VP1-2A^{PRO} precursor (Fig. 8A, left panel). Subsequently, this material is processed into the VP1 and 2A^{PRO} products. Figure 8A shows clearly that there is no difference between the rates of self-processing of the two 2A^{PRO} on their cognate substrates.

To examine the rates of cleavage of eIF4GI in the RRLs, the




FIG. 9. Kinetics of self-processing and eIF4GI cleavage by CVB4 2A^{PRO} R20L. mRNA (~ 10 ng/ μ l) from CVB4 VP1-2A^{PRO} R20L was used to program RRLs. Analysis of self-processing (A) and eIF4GI cleavage (B) were as described in the legend for Fig. 8. Protein standards in kDa are indicated at left of blots. cp_N, N-terminal cleavage product; -RNA, without addition of mRNA.

proteins from the translation reactions were separated by PAGE, blotted onto a nitrocellulose membrane, and probed with an antiserum against the N terminus of eIF4GI. As can be seen in Fig. 8B, intact eIF4GI migrates as a series of bands with molecular masses around 220 kDa (17). The bands have different N termini, which arise from the use of different AUG codons during synthesis of eIF4GI (8, 11). Cleavage of eIF4GI by HRV2A^{PRO} or CVB4 2A^{PRO} at the single recognition site between Arg⁶⁸¹Gly (numbering according to reference 11) generates a series of N-terminal cleavage products, which are detected by the N-terminal antiserum used here. The single C-terminal cleavage fragment is not detected by this antiserum. Figures 8B and C show clearly that there is a difference in kinetics of cleavage of eIF4GI by the two 2A^{PRO}. The half time of eIF4GI cleavage by HRV2 2A^{PRO} was observed to occur between 20 and 30 min, whereas the equivalent point with CVB4 2A^{PRO} was reached only after 180 to 240 min.

Previously, we have shown that the replacement of L17 in HRV2 2A^{PRO} with the corresponding residue from CVB4 2A^{PRO} (R20) results in the inability of the HRV2 2A^{PRO} enzyme to cleave eIF4GI in RRLs (19), supporting the notion that the surface in this region of HRV2 2A^{PRO} constitutes its exosite for binding to eIF4GI. A strong test of this hypothesis would therefore be to improve the cleavage efficiency of CVB4 2A^{PRO} on eIF4GI in the RRL system. Accordingly, we replaced R20 in CVB4 2A^{PRO} with leucine, the equivalent hydrophobic amino acid from HRV2 2A^{PRO}, to create CVB4 2A^{PRO} R20L. Self-processing by this mutant protein took place at wild-type levels (Fig. 9A). In contrast, the rate of eIF4GI cleavage was improved significantly, with the half time being reduced to between 60 and 90 min and cleavage being essentially complete after 240 min (Fig. 9B). These results indicate that the mechanisms of recognition of eIF4GI differ between HRV2 2A^{PRO}

and CVB4 2A^{PRO} and that the hydrophobicity of the surface in the region of the exosite for eIF4GI binding has considerable importance for the cleavage efficiency of HRV2 2A^{PRO} on eIF4GI in RRLs.

Concluding remarks. We have determined the solution structure and conformational dynamics of CVB4 2A^{PRO} covalently linked through its native sequence to eight C-terminal residues of CVB4 VP1. The surface properties of CVB4 2A^{PRO} compared with those of HRV2 2A^{PRO} illustrate one way in which the two enzymes differ in mode of recognition of the cellular substrate eIF4GI, while the conformational dynamics illustrate the extent of the regions of the proteinase involved in self-processing. The multifunctional nature of CVB4 2A^{PRO} makes it a potential therapeutic target at several stages. Inhibition of intramolecular cleavage would interfere with maturation of the virus, while inhibition of mature 2A^{PRO} should both retard translation of the viral polyprotein by interfering with the cleavage of eIF4G proteins and help prevent the pathological consequences of infection that are associated with the cleavage of dystrophin in the heart. The VP1-2A^{PRO} substrate region exchange kinetics observed here indicates that neither of these therapeutic strategies should be severely compromised by binding of the VP1 region. In inhibiting intramolecular cleavage, the population of molecules where the active site cleft is occupied by the VP1-2A^{PRO} substrate region is similar to the population with the active site cleft unoccupied. Thus, the competition for occupancy of the active site between the VP1-2A^{PRO} substrate region and an inhibitor is not significantly in favor of the former. In inhibiting intermolecular cleavage, the relatively low affinity of the VP1-2A^{PRO} substrate region for the active site implies very weak binding of the cleaved VP1 product, and the new N terminus of the protein-

ase may be sequestered by binding away from the active site, as is the case for HRV2 2A^{PRO}.

ACKNOWLEDGMENTS

We acknowledge the use of the BBSRC UK National 800 MHz NMR facility at the University of Cambridge and the provision of FELIX 2000 software from Accelrys, Inc., San Diego, CA. We thank Jeremy Craven for assistance with computing, Paul Thaw for laboratory and spectrometer support, and Cameron McLeod for ICP mass spectrometry measurements.

This work was supported by the British Heart Foundation as an Intermediate Research Fellowship awarded to N.J.B., by the BBSRC, and by grants P-16189 and P-17988 from the Austrian Science Foundation to T.S.

REFERENCES

- Baboonian, C., M. J. Davies, J. C. Booth, and W. J. McKenna. 1997. Coxsackie B viruses and human heart disease. *Curr. Top. Microbiol. Immunol.* **223**:31–52.
- Badorff, C., N. Berkely, S. Mehrotra, J. W. Talhouk, R. E. Rhoads, and K. U. Knowlton. 2000. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. *J. Biol. Chem.* **275**: 11191–11197.
- Badorff, C., G.-H. Lee, B. J. Lamphear, M. E. Martone, K. P. Campbell, R. E. Rhoads, and K. U. Knowlton. 1999. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. *Nat. Med.* **5**:320–326.
- Barbato, G., D. O. Cicero, M. C. Nardi, C. Steinkühler, R. Cortese, R. De Francesco, and R. Bazzo. 1999. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. *J. Mol. Biol.* **289**:371–384.
- Barbato, G., D. O. Cicero, F. Cordier, F. Narjes, B. Gerlach, S. Sambucini, S. Grzesiek, V. G. Matassa, R. De Francesco, and R. Bazzo. 2000. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain. *EMBO J.* **19**:1195–1206.
- Bax, A., G. M. Clore, and A. M. Gronenborn. 1990. ¹H-¹H correlation via isotropic mixing of ¹³C magnetisation: a new 3D approach for assigning ¹H and ¹³C spectra of ¹³C-enriched proteins. *J. Magn. Reson.* **88**:425–431.
- Belsham, G. J., and N. Sonenberg. 1996. RNA-protein interactions in regulation of picornaviral RNA translation. *Microbiol. Rev.* **60**:499–511.
- Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**:248–254.
- Bradley, C. A., J. C. Padovan, T. L. Thompson, C. A. Benoit, B. T. Chait, and R. E. Rhoads. 2002. Mass spectrometric analysis of the N terminus of translational initiation factor eIF4G-1 reveals novel isoforms. *J. Biol. Chem.* **277**:12559–12571.
- Brunger, A. T. 1992. X-PLOR version 3.1: a system for X-ray crystallography and NMR. Yale University Press, New Haven, Conn.
- Brunger, A. T., P. D. Adams, G. M. Clore, W. L. Delano, P. Gros, R. W. Grosse-Kunstleve, J.-S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography and NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr. D* **54**:905–921.
- Byrd, M. P., M. Zamora, and R. E. Lloyd. 2002. Generation of multiple isoforms of eukaryotic translation initiation factor 4GI by use of alternate translation initiation codons. *Mol. Cell. Biol.* **22**:4499–4511.
- Cavanagh, J., W. J. Fairbrother, A. G. Palmer, and N. J. Skelton. 1995. Protein NMR spectroscopy: principles and practice. Academic Press, Inc., San Diego, Calif.
- Chen, J., and K. R. Chien. 1999. Complexity in simplicity: monogenic disorders and complex cardiomyopathies. *J. Clin. Investig.* **103**:1483–1485.
- Clubb, R. T., V. Thanabal, and G. Wagner. 1992. A constant-time 3D pulse scheme to correlate intraresidue ¹HN, ¹⁵N and ¹³C chemical shifts in ¹⁵N-¹³C labeled proteins. *J. Magn. Reson.* **97**:213–217.
- Cornilescu, G., F. Delaglio, and A. Bax. 1999. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. *J. Biomol. NMR* **13**:289–302.
- DeLano, W. L. 2002. The PyMOL molecular graphics system. DeLano Scientific LLC, San Carlos, Calif. [Online.] <http://www.pymol.org>.
- Etchison, D., S. C. Milburn, I. Edery, N. Sonenberg, and J. W. B. Hershey. 1982. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220 kDa polypeptide associated with eukaryotic initiation factor 3 and a cap binding protein complex. *J. Biol. Chem.* **257**:14806–14810.
- Ferrin, T. E., C. C. Huang, L. E. Jarvis, and R. Langridge. 1988. The MIDAS display system. *J. Mol. Graph.* **6**:13–27.
- Foeger, N., E. M. Schmid, and T. Skern. 2003. Human rhinovirus 2 A^{PRO} recognition of eukaryotic initiation factor 4GI. Involvement of an exosite. *J. Biol. Chem.* **278**:33200–33207.
- Glaser, W., and T. Skern. 2000. Extremely efficient cleavage of eIF4G by picornaviral proteinases L and 2A in vitro. *FEBS Lett.* **480**:151–155.
- Glaser, W., A. Triendl, and T. Skern. 2003. The processing of eIF4GI by human rhinovirus 2 A^{PRO}: relationship to self-cleavage and role of zinc. *J. Virol.* **77**:5021–5025.
- Gradi, A., Y. V. Svitkin, H. Imataka, and N. Sonenberg. 1998. Proteolysis of human eukaryotic initiation translation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. *Proc. Natl. Acad. Sci. USA* **95**:11089–11094.
- Grzesiek, S., and A. Bax. 1992. Improved 3D triple-resonance NMR techniques applied to a 31 kDa protein. *J. Magn. Reson.* **96**:432–440.
- Grzesiek, S., and A. Bax. 1993. Amino acid type determination in the sequential assignment procedure of ¹³C/¹⁵N-enriched proteins. *J. Biomol. NMR* **3**:185–204.
- Hentze, M. W. 1997. eIF4G—a multipurpose ribosome adaptor. *Science* **275**:500–501.
- Kerekatte, V., B. D. Keiper, C. Badorff, A. Cai, K. U. Knowlton, and R. E. Rhoads. 1999. Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? *J. Virol.* **73**:709–717.
- Koenig, M., A. P. Monaco, and L. M. Kunkel. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell* **53**:219–226.
- Kördel, J., N. J. Skelton, M. Akke, A. G. Palmer, and W. J. Chazin. 1992. Backbone dynamics of calcium-loaded calbindin D9k studied by two-dimensional proton-detected ¹⁵N NMR spectroscopy. *Biochemistry* **31**:4856–4866.
- Kraulis, P. J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. *J. Appl. Crystallogr.* **24**:946–950.
- Lamphear, B. J., R. Kirchweger, T. Skern, and R. E. Rhoads. 1995. Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. *J. Biol. Chem.* **270**:21975–21983.
- Laskowski, R. A., J. A. C. Rullmann, M. W. MacArthur, R. Kaptein, and J. M. Thornton. 1996. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *J. Biomol. NMR* **8**:477–486.
- Liebig, H.-D., E. Ziegler, R. Yan, K. Hartmuth, H. Klump, H. Kowalski, D. Blaas, W. Sommergruber, L. Frasel, B. Lamphear, R. Rhoads, E. Kuechler, and T. Skern. 1993. Purification of two picornaviral 2A proteinases: interaction with eIF-4γ and influence on *in vitro* translation. *Biochemistry* **32**: 7581–7588.
- Malhotra, S. B., K. A. Hart, H. J. Klamut, N. S. Thomas, S. E. Bodrug, A. Burghes, M. Bobrow, P. S. Harper, M. W. Thompson, et al. 1988. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. *Science* **242**:755–759.
- Martin, J. R., F. A. Mulder, Y. Karimi-Nejad, J. van der Zwan, M. Mariani, D. Schipper, and R. Boelens. 1997. The solution structure of serine protease PB92 from *Bacillus alcalophilus* presents a rigid fold with a flexible substrate-binding site. *Structure* **5**:521–532.
- McCoy, M. A., M. M. Senior, J. J. Gesell, L. Ramanathan, and D. F. Wyss. 2001. Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. *J. Mol. Biol.* **305**:1099–1110.
- Merrit, E. A., and D. J. Bacon. 1997. Raster3D: photorealistic molecular graphics. *Methods Enzymol.* **277**:505–524.
- Neri, D., Y. Zyperski, G. Otting, H. Senn, and K. Wüthrich. 1989. Stereospecific NMR assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional ¹³C labeling. *Biochemistry* **28**:7510–7516.
- Nicholls, A., K. A. Sharp, and B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins* **11**:281–296.
- Nigro, G., L. I. Comi, L. Politano, and R. J. Bain. 1990. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int. J. Cardiol.* **26**:271–277.
- Omichinski, J. G., G. M. Clore, E. Appella, K. Sakaguchi, and A. M. Gronenborn. 1990. High-resolution three-dimensional structure of a single zinc finger from a human enhancer binding protein in solution. *Biochemistry* **29**:9324–9334.
- Pascal, S. M., D. R. Muhandiram, T. Yamazaki, J. D. Forman-Kay, and L. E. Kay. 1994. Simultaneous acquisition of ¹⁵N- and ¹³C-edited NOE spectra of proteins dissolved in H₂O. *J. Magn. Reson. B* **103**:197–201.
- Pestova, T. V., V. G. Kolupaeva, I. B. Lomakin, E. V. Pilipenko, I. N. Shatsky, V. I. Agol, and C. U. T. Hellen. 2001. Molecular mechanisms of translation initiation in eukaryotes. *Proc. Natl. Acad. Sci. USA* **98**:7029–7036.
- Petersen, J. F. W., M. M. Cherney, H.-D. Liebig, T. Skern, E. Kuechler, and M. N. G. James. 1999. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. *EMBO J.* **18**:5463–5475.
- Read, R. J., M. Fujinaga, A. R. Sielecki, and M. N. G. James. 1983. Structure

- of the complex of *Streptomyces griseus* protease B and the third domain of the turkey ovomucoid inhibitor at 1.8 Å resolution. *Biochemistry* **22**:4420–4433.
45. Reed, M. A. C., A. M. Hounslow, K. H. Sze, I. G. Barsukov, L. L. P. Hosszu, A. R. Clarke, C. J. Craven, and J. P. Waltho. 2003. Effects of domain dissection on the folding and stability of the 43 kDa protein PGK probed by NMR. *J. Mol. Biol.* **330**:1189–1201.
 46. Sachs, A. B., P. Sarnow, and M. W. Hentz. 1997. Starting at the beginning, middle and end: translation initiation in eukaryotes. *Cell* **89**:831–838.
 47. Sarkany, Z., T. Skern, and L. Polgar. 2000. Characterization of the active site thiol group of rhinovirus 2A proteinase. *FEBS Lett.* **481**:289–292.
 48. Sauter, N. K., T. Mau, S. D. Rader, and D. A. Agard. 1998. Structure of α -lytic protease complexed with its pro region. *Nat. Struct. Biol.* **5**:945–950.
 49. Skern, T., B. Hampoelz, E. Bergmann, A. Guarné, J. Petersen, I. Fita, and M. N. G. James. 2002. Structure and function of picornaviral proteinases, p. 199–212. *In* B. Semler and E. Wimmer (ed.), *Molecular biology of picornaviruses*. ASM Press, Washington, D.C.
 50. Sole, M. J., and P. Liu. 1993. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. *J. Am. Coll. Cardiol.* **22**:99A–105A.
 51. Sommergruber, W., H. Ahorn, A. Zoephel, I. Maurer-Fogy, F. Fessl, G. Schnorrenberg, H.-D. Liebig, D. Blaas, E. Kuechler, and T. Skern. 1992. Cleavage specificity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A. *J. Biol. Chem.* **267**:22639–22644.
 52. Sommergruber, W., H. Ahorn, H. Klump, J. Seipelt, A. Zoephel, F. Fessl, E. Krystek, D. Blaas, E. Kuechler, H.-D. Liebig, and T. Skern. 1994. 2A proteinases of Coxsackie- and Rhinovirus cleave peptides derived from eIF-4 γ via a common recognition motif. *Virology* **198**:741–745.
 53. Sommergruber, W., C. Casari, F. Fessl, J. Seipelt, and T. Skern. 1994. The 2A proteinase of human rhinovirus is a zinc containing enzyme. *Virology* **204**:815–818.
 54. Straub, V., and K. P. Campbell. 1997. Muscular dystrophies and the dystrophin-glycoprotein complex. *Curr. Opin. Neurol.* **10**:168–175.
 55. Towbin, J. A., J. F. Hejtmancik, P. Brink, B. Gelb, X. M. Zhu, J. S. Chamberlain, E. R. McCabe, and M. Swift. 1993. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy dystrophin gene at the Xp21 locus. *Circulation* **87**:1854–1865.
 56. Toyoda, H., M. J. H. Nicklin, M. G. Murray, C. W. Anderson, J. J. Dunn, F. W. Studier, and E. Wimmer. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. *Cell* **45**:761–770.
 57. Voss, T., R. Meyer, and W. Sommergruber. 1995. Spectroscopic characterization of rhinoviral 2A: Zn is essential for the structural integrity. *Protein Sci.* **4**:2526–2531.
 58. Vuister, G. W., and A. Bax. 1992. Resolution enhancement and spectral editing of uniformly enriched ^{13}C protein by homonuclear broadband decoupling. *J. Magn. Reson.* **98**:428–435.
 59. Whitehead, B., M. Tessari, P. Dux, R. Boelens, R. Kaptein, and G. W. Vuister. 1997. A ^{15}N -filtered 2D ^1H TOCSY experiment for assignment of aromatic ring resonances and selective identification of tyrosine ring resonances in proteins: description and application to photoactive yellow protein. *J. Biomol. NMR* **9**:313–316.
 60. Wittekind, M., and L. Mueller. 1993. HNCACB, a high-sensitivity 3D NMR experiment to correlate amide-proton and nitrogen resonances with the alpha- and beta-carbon resonances in proteins. *J. Magn. Reson. B* **101**:201–205.
 61. Xiong, D., G.-H. Lee, C. Badorff, A. Dorner, S. Lee, P. Wolf, and K. U. Knowlton. 2002. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. *Nat. Med.* **8**:872–877.